What is the 13F Pro Quality Score for ANNX?

13F Pro ranks Annexon, Inc. (ANNX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View ANNX's current score at https://13fpro.ai/research/ANNX (free sign-up required for the full ranking).

Which hedge funds own the most ANNX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of ANNX include Redmile Group,, BlackRock,, FMR. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/ANNX as soon as new 13F filings post.

Where does 13F Pro source ANNX data?

All Annexon, Inc. fundamentals and ownership data come directly from SEC EDGAR. Annexon, Inc. files with the SEC under CIK 1528115. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is ANNX in?

Annexon, Inc. (ANNX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is ANNX research updated on 13F Pro?

ANNX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Annexon, Inc.(ANNX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1528115 ANNX stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

ANNX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Annexon, Inc. (ANNX), a Healthcare sector company. ANNX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Annexon, Inc. reports net income of $-44.1M, free cash flow of $-46.8M. Top institutional holders of ANNX by reported 13-F value include Redmile Group,, BlackRock,, FMR, based on the most recent SEC filings. ANNX trades on the Nasdaq exchange and files with the SEC under CIK 1528115. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ANNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Annexon, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-44.1M

Free Cash Flow

Q1 2026

$-46.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

-49.6% YoY

$-206.7MFY 2025

FY21 $-130.3MFY22 $-141.9MFY24 $-138.2MFY25 $-206.7M

Operating Income

-40.5% YoY

$-216.4MFY 2025

FY21 $-130.7MFY22 $-145.6MFY24 $-154.1MFY25 $-216.4M

EPS (Diluted)

-32.7% YoY

$-1.34FY 2025

FY21 $-3.40FY22 $-2.60FY24 $-1.01FY25 $-1.34

Total Assets

-20.7% YoY

$277.6MFY 2025

FY21 $287.0MFY22 $285.1MFY24 $350.1MFY25 $277.6M

Op. Cash Flow

-57.9% YoY

$-186.4MFY 2025

FY21 $-106.1MFY22 $-116.3MFY24 $-118.0MFY25 $-186.4M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020
Net Income	$-206.7M -49.6%	$-138.2M +2.6%	$-141.9M -8.9%	$-130.3M -105.5%	$-63.4M
Operating Income	$-216.4M -40.5%	$-154.1M -5.8%	$-145.6M -11.4%	$-130.7M -105.9%	$-63.5M
EPS (Diluted)	$-1.34 -32.7%	$-1.01 +61.2%	$-2.60 +23.5%	$-3.40	—
Total Assets	$277.6M -20.7%	$350.1M +22.8%	$285.1M -0.7%	$287.0M -19.4%	$355.9M
Operating Cash Flow	$-186.4M -57.9%	$-118.0M -1.5%	$-116.3M -9.6%	$-106.1M -99.9%	$-53.1M

AI Insight: ANNX Financial Trends

Annexon's quarterly losses remain elevated at $44-55M with equity declining from $361M to $205M over eight quarters.

• Net losses fluctuated between $30M and $55M quarterly with no clear improvement trend over eight quarters.

• Equity declined 43% from $361M in Q2 2024 to $205M in Q1 2026.

• Operating cash flow burn averaged $40M quarterly, ranging from $22M to $52M.

⚠ Equity increased to $212M in Q4 2025 from $161M prior quarter, suggesting potential capital raise.

⚠ Current burn rate gives roughly 1-2 years of runway based on latest equity balance.

AI Insight: ANNX Ratio Trends

Annexon shows sequential improvement with ROE recovering from -136.1% in Q3 2025 to -86.3% in Q1 2026, though losses remain substantial.

• ROE improved from -136.1% in Q3 2025 to -86.3% in Q1 2026, marking two consecutive quarters of recovery.

• ROA strengthened from -95.9% in Q3 2025 to -67.2% in Q1 2026, following similar improvement trajectory.

• ROIC recovered to -90.1% in Q1 2026 after being unmeasurable in Q2-Q3 2025 due to negative invested capital.

⚠ All profitability metrics remain deeply negative despite recent improvements, indicating continued substantial losses.

⚠ Operating and net profit margins unavailable across all periods, suggesting minimal or negative revenues typical of development-stage biotech.

Get alerted when ANNX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Annexon, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of ANNX

Redmile Group, LLC
$80.6M14,549,768 sh
BlackRock, Inc.
$60.6M10,938,509 sh
FMR LLC
$58.9M10,635,648 sh
BVF INC/IL
$48.2M8,698,173 sh
STATE STREET CORP
$38.3M6,919,255 sh
VANGUARD CAPITAL MANAGEMENT LLC
$33.0M5,956,589 sh
Bain Capital Life Sciences Investors, LLC
$28.9M5,212,674 sh
Bellevue Group AG
$28.6M5,157,290 sh
MAK CAPITAL ONE LLC
$26.2M4,724,043 sh
ADAGE CAPITAL PARTNERS GP, L.L.C.
$23.8M4,300,000 sh

Fund	Value	Shares
Redmile Group, LLC	$80.6M	14,549,768
BlackRock, Inc.	$60.6M	10,938,509
FMR LLC	$58.9M	10,635,648
BVF INC/IL	$48.2M	8,698,173
STATE STREET CORP	$38.3M	6,919,255
VANGUARD CAPITAL MANAGEMENT LLC	$33.0M	5,956,589
Bain Capital Life Sciences Investors, LLC	$28.9M	5,212,674
Bellevue Group AG	$28.6M	5,157,290
MAK CAPITAL ONE LLC	$26.2M	4,724,043
ADAGE CAPITAL PARTNERS GP, L.L.C.	$23.8M	4,300,000

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put ANNX on your watchlist

Track score changes the day Annexon, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is ANNX a good stock to buy?

13F Pro's AI-powered analysis of Annexon, Inc. (ANNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ANNX are available on the ANNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own ANNX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ANNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Annexon, Inc.'s investment landscape.